Michelle Nguyen, MD
Gastroenterology · Los Gatos, CANPI 1811967920
Payments from drug & device makers
Across 514 payments — averaging $202.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Capsovision, Inc.$67K
- AbbVie$28K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Gilead$3K
- Johnson & Johnson$458
- Nestle Healthcare Nutrition Inc.$341
- plus $3K from 32 others
What the payments were for
- Consulting fees$69,93967%
- Speaking & faculty fees$25,35024%
- Travel & lodging$2020%
- Food & beverage$8,6638%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Capsovision, Inc. | 8 | $66,809 |
| AbbVie | 227 | $27,666 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 97 | $3,412 |
| Gilead | 29 | $2,992 |
| Johnson & Johnson | 22 | $458 |
| Nestle Healthcare Nutrition Inc. | 23 | $341 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $283 |
| Bristol Myers Squibb | 14 | $186 |
| Aimmune Therapeutics, Inc. | 7 | $184 |
| Celltrion USA Inc. | 8 | $180 |
| Pfizer | 7 | $170 |
| Ardelyx, Inc. | 6 | $152 |
| Merck | 8 | $150 |
| Amarin Pharma, Inc. | 1 | $143 |
| Braintree Laboratories, Inc. | 7 | $141 |
| Eisai Inc. | 1 | $125 |
| Ironwood Pharmaceuticals, Inc | 5 | $86 |
| Intercept Pharmaceuticals, Inc. | 3 | $80 |
| Redhill Biopharma Inc. | 4 | $70 |
| Sanofi | 2 | $70 |
| Lilly USA, LLC | 3 | $59 |
| Vivus LLC | 2 | $49 |
| Novo Nordisk | 2 | $47 |
| Coloplast | 2 | $44 |
| Vertos Medical, Inc. | 1 | $38 |
| Biotissue Holdings Inc. | 1 | $36 |
| Fresenius Kabi USA, LLC | 1 | $35 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Alfasigma USA, Inc. | 1 | $29 |
| AstraZeneca | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Micro-tech Endoscopy USA, Inc. | 1 | $18 |
| QOL Medical, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,255 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 32 | $172,272 |
| ZenpepLipase/Protease/Amylase | 22 | $104,253 |
| XifaxanRifaximin | 11 | $25,262 |
| MotegrityPrucalopride Succinate | 12 | $18,989 |
| LinzessLinaclotide | 11 | $12,246 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 16 | $2,608 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 14 | $2,026 |
| Pantoprazole Sodium | 95 | $1,479 |
| Colestipol Hcl | 14 | $1,115 |
| CholestyramineCholestyramine (With Sugar) | 20 | $1,110 |
| Famotidine | 83 | $973 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 13 | $785 |
| Omeprazole | 46 | $444 |
| Ondansetron OdtOndansetron | 18 | $436 |
| Sucralfate | 11 | $277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $27,666 | $184,51843 claims |
| Aimmune Therapeutics, Inc.Zenpep | $184 | $104,25322 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $3,412 | $27,28825 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $283 | $18,98912 claims |
| Braintree Laboratories, Inc.Sutab | $141 | $2,60816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Los Gatos
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gregory WienerChula Vista$3.5M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
- Brigid BolandSan Diego$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.